A Phase 1 interventional study of Vorico Injection 200mg(Voriconazole) and Vfend®(Voriconazole) IV 200mg in Aspergillus Infections, Candida Infections and Fungal Infections, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-18.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.
Among the 17 studies testing voriconazole in Aspergillosis, this one is the 8th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1, and was the 16th registered.
134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.
Browse Aspergillosis studies →None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →
Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 19 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 4
First in 1997; this study’s year is marked. 1 started in 2015.
This study's enrollment of 24 is below the median of 47 across 75 interventional studies indexed under Aspergillosis.
Median enrollment 24 across the 17 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
Chong Kun Dang Pharmaceutical has 1 study filed under Aspergillosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing voriconazole in Aspergillosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
To healthy volunteers subjects of twenty four(24), following treatments are administered dosing in each period injected wash-out period is a minimum of 7days. Treatment A(Test Drug): Vorico Injection 200mg(Voriconazole) for Single Dose Treatment B(Reference Drug): Vfend® IV 200mg for Single Dose Pharmacokinetic blood samples are collected up to 24hrs.
Safety and pharmacokinetic are assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Who agreed to do during testing
A male who did not have vasectomy has to follow the clinically proven contraceptive methods* listed under, and who agreed not to donate sperm during the test
* Clinically proven contraceptive method: intrauterine device (ex. Lippes Loop, Minera), chemical contraceptive (spermicides) for use with physical contraceptive method (males or females), contraceptive implants (ex. Implanon), tubal ligation or laparoscopy (common methods of tubal ligation)
A woman of childbearing age who agreed on constant use of a medically disproven Dual Protection method** and spermicides except hormonal contraceptive, and who also agreed not to breastfeed.
Exclusion Criteria:
Who falls under the following results
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
Drug: Vorico Injection 200mg(Voriconazole) · Drug: Vfend®(Voriconazole) IV 200mg
Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
Drug: Vorico Injection 200mg(Voriconazole) · Drug: Vfend®(Voriconazole) IV 200mg
Vorico Injection 200mg(Voriconazole) to administered intravenously once
Vfend®(Voriconazole) IV 200mg to administered intravenously once
Cmax of Voriconazole
The blood sampleing coleected from the subjects was analyzed and result was obtained.
Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
AUCt of Voriconazole
The blood sampleing coleected from the subjects was analyzed and result was obtained.
Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
Tmax of Voriconazole
The blood sampleing coleected from the subjects was analyzed and result was obtained.
Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
AUCinf of Voriconazole
The blood sampleing coleected from the subjects was analyzed and result was obtained.
Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
AUCt/AUCinf
The blood sampleing coleected from the subjects was analyzed and result was obtained.
Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
Kel (Elemination Rate Constant)
The blood sampleing coleected from the subjects was analyzed and result was obtained.
Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
t1/2
The blood sampleing coleected from the subjects was analyzed and result was obtained.
Time frame: 0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs
| Milestone | TR Group | RT Group |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
The blood sampleing coleected from the subjects was analyzed and result was obtained.
| ng/mL | Reference | Test |
|---|---|---|
| Cmax of Voriconazole | 2433.7 ± 2456.9 | 1997.0 ± 406.2 |
The blood sampleing coleected from the subjects was analyzed and result was obtained.
| hr*ng/mL | Reference | Test |
|---|---|---|
| AUCt of Voriconazole | 6966.17 ± 2856.10 | 7469.78 ± 3125.73 |
The blood sampleing coleected from the subjects was analyzed and result was obtained.
| hr | Reference | Test |
|---|---|---|
| Tmax of Voriconazole | 1.57 ± 0.03 | 1.58 ± 0.04 |
The blood sampleing coleected from the subjects was analyzed and result was obtained.
| hr*ng/mL | Reference | Test |
|---|---|---|
| AUCinf of Voriconazole | 8159.24 ± 4905.05 | 8631.50 ± 4401.54 |
The blood sampleing coleected from the subjects was analyzed and result was obtained.
| Ratio | Reference | Test |
|---|---|---|
| AUCt/AUCinf | 0.94 ± 0.10 | 0.90 ± 0.09 |
The blood sampleing coleected from the subjects was analyzed and result was obtained.
| 1/hr | Reference | Test |
|---|---|---|
| Kel (Elemination Rate Constant) | 0.10 ± 0.03 | 0.10 ± 0.04 |
The blood sampleing coleected from the subjects was analyzed and result was obtained.
| hr | Reference | Test |
|---|---|---|
| t1/2 | 8.42 ± 4.61 | 7.98 ± 2.92 |
Collected over 1 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reference | 0/23 (0%) | 0/23 (0%) | 21/23 (91.3%) |
| Test | 0/24 (0%) | 0/24 (0%) | 22/24 (91.7%) |
| Event | Reference | Test |
|---|---|---|
| photophobiaEye disorders | 18/23 | 21/24 |
| dizzinessVascular disorders | 3/23 | 3/24 |
| vision blurredEye disorders | 2/23 | 0/24 |
| headacheNervous system disorders | 0/23 | 2/24 |
| colour blindness acquiredEye disorders | 1/23 | 0/24 |
| visual imparimentEye disorders | 1/23 | 1/24 |
| white blood cells urine positiveInvestigations | 1/23 | 0/24 |
| nasal congestionRespiratory, thoracic and mediastinal disorders | 1/23 | 0/24 |
| epistaxisVascular disorders | 1/23 | 0/24 |
| blood glucose increasedInvestigations | 0/23 | 1/24 |
24 subejcts were used for baseline analysis.
| Age, Categorical(Participants) | TR Group | RT Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 12 | 24 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | TR Group | RT Group | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 12 | 12 | 24 |
The record gives a start of Sep 2015, a primary completion of Oct 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2020, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole
Chong Kun Dang Pharmaceutical →